The study results indicated that avelumab maintenance did not demonstrate superior OS outcomes compared to continued CTH in patients with advanced GC or GEJ, both in the overall population and in a predefined PD-L1-positive subgroup [182]. Here, CD274 is linked to gastric cancer.